MAPT and Alzheimer disease: Aducanumab, a mAb with selective action on aggregated forms of Aβ, is the first to be approved by the FDA for the treatment of AD [36]: it has the ability to reduce the Aβ overload of the brain and, in theory, to limit, block or prevent the damage caused by Aβ, while reducing p-Tau.